Indomethacin Prophylaxis Is Associated with Reduced Risk of Intraventricular Hemorrhage in Extremely Preterm Infants Born in the Context of Amniotic Infection Syndrome

Background: Amniotic infection syndrome (AIS) with perinatal inflammation may increase the susceptibility to intraventricular hemorrhage (IVH) in preterm infants. Given its anti-inflammatory and ductus arteriosus constricting capacities, we hypothesized that prophylactic administration of indomethacin reduces the incidence, severity, and consequences of IVH in the context of perinatal inflammation. Methods: We evaluated data of infants born between 2009 and 2020 of 22 + 0–25+6 weeks of gestation from 68 German Neonatal Network centers. The effect of indomethacin prophylaxis on outcomes was analyzed in univariate analyses and multivariate regression models including a subgroup of infants with available data on 5-year follow-up. Results: 4760 infants were included with a median gestational age of 24.6 SSW [interquartile range (IQR) 24.1w–25.2w] and a birth weight of 640 g [IQR 550–750 g]. 1767/4760 (37.1%) preterm infants were born in the context of AIS and 527/4760 (11.1%) received indomethacin prophylaxis. AIS infants receiving prophylactic indomethacin had lower rates of IVH (32.7% vs. 36.9%, p = 0.04), IVH III/IV (9.7% vs. 16.0%, p = 0.02) and the combined outcome of severe IVH or death (15.9% vs. 23.2%, p = 0.01) as compared to infants without prophylaxis. Multivariate logistic regression analyses confirmed our observations. In a subgroup analysis of 730 preterm infants at 5 years of age, we did not find any correlation between prophylactic indomethacin and intelligence quotient <70 or cerebral palsy. Conclusions: Our observational data demonstrate that prophylactic indomethacin is associated with a reduced risk of IVH in the highly vulnerable subgroup of preterm infants <26 weeks of gestation born from AIS.

[1]  E. Rogers,et al.  Reduction of Severe Intraventricular Hemorrhage in Preterm Infants: A Quality Improvement Project. , 2022, Pediatrics.

[2]  S. Merhar,et al.  Mortality, In-Hospital Morbidity, Care Practices, and 2-Year Outcomes for Extremely Preterm Infants in the US, 2013-2018. , 2022, JAMA.

[3]  D. Wolke,et al.  Preterm birth: Educational and mental health outcomes , 2021, Clinical child psychology and psychiatry.

[4]  B. Taylor,et al.  Gestational Age-Dependent Variations in Effects of Prophylactic Indomethacin on Brain Injury and Intestinal Injury. , 2021, The Journal of pediatrics.

[5]  R. Cotton,et al.  Outcomes in infants < 29 weeks of gestation following single-dose prophylactic indomethacin , 2020, Journal of Perinatology.

[6]  P. McNamara,et al.  Combined Multimodal Cerebral Monitoring and Focused Hemodynamic Assessment in the First 72 h in Extremely Low Gestational Age Infants , 2020, Neonatology.

[7]  W. Göpel,et al.  Less invasive surfactant administration (LISA): chances and limitations , 2019, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[8]  B. Vohr,et al.  Neurodevelopmental Impairment Among Extremely Preterm Infants in the Neonatal Research Network , 2018, Pediatrics.

[9]  B. Poindexter,et al.  Trends in Care Practices, Morbidity, and Mortality of Extremely Preterm Neonates, 1993-2012. , 2015, JAMA.

[10]  J. Carlin,et al.  Using the Gross Motor Function Classification System to describe patterns of motor severity in cerebral palsy , 2011, Developmental medicine and child neurology.

[11]  Z. Ungvari,et al.  Neuroprotection in a rabbit model of intraventricular haemorrhage by cyclooxygenase-2, prostanoid receptor-1 or tumour necrosis factor-alpha inhibition. , 2010, Brain : a journal of neurology.

[12]  S. Straube,et al.  Birth weight percentile charts based on daily measurements for very preterm male and female infants at the age of 154–223 days , 2010, Journal of perinatal medicine.

[13]  P. Davis,et al.  Cochrane Review: Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants , 2010 .

[14]  P. Gastmeier,et al.  Incidence of healthcare-associated infections in high-risk neonates: results from the German surveillance system for very-low-birthweight infants. , 2008, The Journal of hospital infection.

[15]  R. Clark,et al.  Emerging trends in acquired neonatal intestinal disease: is it time to abandon Bell's criteria? , 2007, Journal of Perinatology.

[16]  J. Dambrosia,et al.  Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. , 2002, The Journal of pediatrics.

[17]  D B Knight,et al.  The treatment of patent ductus arteriosus in preterm infants. A review and overview of randomized trials. , 2001, Seminars in neonatology : SN.

[18]  K C Schneider,et al.  Neurodevelopmental outcome at 36 months' corrected age of preterm infants in the Multicenter Indomethacin Intraventricular Hemorrhage Prevention Trial. , 1996, Pediatrics.

[19]  P. Eken,et al.  The spectrum of leukomalacia using cranial ultrasound , 1992, Behavioural Brain Research.

[20]  A. Ohlsson,et al.  Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. , 1988, Pediatrics.

[21]  L. Papile,et al.  Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. , 1978, The Journal of pediatrics.

[22]  M. J. Bell,et al.  Neonatal Necrotizing Enterocolitis: Therapeutic Decisions Based upon Clinical Staging , 1978, Annals of surgery.

[23]  J. Goldberg.  Committee Opinion No 700: Methods for Estimating the Due Date. , 2017, Obstetrics and gynecology.

[24]  G. Marshall,et al.  A risk prediction model for severe intraventricular hemorrhage in very low birth weight infants and the effect of prophylactic indomethacin , 2014, Journal of Perinatology.

[25]  A. Fanaroff.  Neurodevelopmental Outcome of Preterm Infants with Severe Intraventricular Hemorrhage and Therapy for Post-Hemorrhagic Ventricular Dilatation , 2009 .